Oncotelic Therapeutics, Inc.

Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops antisense and small molecule injectable drugs for the treatment of cancer, focusing on orphan oncology indications. The company was formed in New York in 1988 as OXiGENE, Inc., reincorporated in Delaware in 1992, changed its name to Mateon Therapeutics, Inc. in 2016, and then to Oncotelic Therapeutics, Inc. in November 2020. Oncotelic conducts business through its wholly-owned subsidiaries: Oncotelic, Inc., PointR Data, Inc., Pet2DAO, Inc., and EdgePoint AI, Inc., which has non-controlling interests. The company is developing OT-101 and five additional compounds for various cancers and COVID-19 through its joint venture, GMP Biotechnology Limited, with Dragon Overseas Capital, Limited. GMP Bio is also developing Artemisinin for COVID-19 and AI technologies for clinical development and manufacturing, along with 5 additional nanoparticle compounds. Oncotelic also acquired apomorphine for Parkinson's Disease, erectile dysfunction, and female sexual dysfunction. The company is evaluating OXi4503 for acute myeloid leukemia and myelodysplastic syndromes, and CA4P in combination with a checkpoint inhibitor for advanced metastatic melanoma. Oncotelic plans to address the animal health industry through Pet2DAO. Following a reverse merger in 2019, the company realigned its pipeline to focus on various cancers, including rare pediatric cancers. Its principal corporate office is in the United States at 29397 Agoura Road, Suite 107, Agoura Hills, CA 91301.